102
Participants
Start Date
November 14, 2018
Primary Completion Date
July 31, 2027
Study Completion Date
July 31, 2029
Pembrolizumab
Anti-PD-1 targeted immunotherapy
Stereotactic Body Radiation Therapy (SBRT)
High-precision radiotherapy
RECRUITING
Northwell Health, Lake Success
RECRUITING
University of Pittsburgh Medical Center Shadyside, Pittsburgh
RECRUITING
Penn State Milton S. Hershey Medical Center, Hershey
RECRUITING
Fox Chase Cancer Center, Philadelphia
RECRUITING
Cleveland Clinic - Weston, Weston
RECRUITING
Moffitt Cancer Center, Tampa
RECRUITING
University of Louisville, James Graham Brown Cancer Center, Louisville
RECRUITING
Ohio State University, Columbus
WITHDRAWN
University Hospitals Cleveland Medical Center, Cleveland
RECRUITING
Cleveland Clinic, Cleveland
RECRUITING
University of Cincinnati Cancer Center - UC Medical Center, Cincinnati
WITHDRAWN
Henry Ford Hospital, Detroit
RECRUITING
Medical College of Wisconsin, Milwaukee
RECRUITING
Washington University St. Louis, St Louis
COMPLETED
University of Texas Southwestern, Dallas
RECRUITING
University of Arizona Cancer Center - North Campus, Tucson
RECRUITING
Boston Medical Center, Boston
RECRUITING
Cross Cancer Institute, Edmonton
RECRUITING
Centre Hospitalier de l'université de Montréal, Montreal
RECRUITING
McGill University, Montreal
WITHDRAWN
CHU de Quebec - Universite Laval, Québec
Merck Sharp & Dohme LLC
INDUSTRY
RTOG Foundation, Inc.
OTHER